A Study to Evaluate the Effect of MCI-186 at Therapeutic and Supra-Therapeutic Doses on the QT Interval(QT)/Corrected QT Interval(QTc) Interval in Healthy Subjects

NCT04029090 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

27

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Adult Subjects

Interventions

DRUG: MCI-186
DRUG: MCI-186
DRUG: Placebo

Sponsor

Tanabe Pharma Corporation